RU2445975C2 - Продление срока выживаемости аллотрансплантата путем ингибирования активности комплемента - Google Patents

Продление срока выживаемости аллотрансплантата путем ингибирования активности комплемента Download PDF

Info

Publication number
RU2445975C2
RU2445975C2 RU2008139118/15A RU2008139118A RU2445975C2 RU 2445975 C2 RU2445975 C2 RU 2445975C2 RU 2008139118/15 A RU2008139118/15 A RU 2008139118/15A RU 2008139118 A RU2008139118 A RU 2008139118A RU 2445975 C2 RU2445975 C2 RU 2445975C2
Authority
RU
Russia
Prior art keywords
complement
specified
inhibits
drug
allograft
Prior art date
Application number
RU2008139118/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2008139118A (ru
Inventor
Расселл П. РОТЕР (US)
Расселл П. Ротер
Хао ВАН (CA)
Хао ВАН
Чжень ЧЖУН (CA)
Чжень ЧЖУН
Original Assignee
Алексион Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38475394&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2445975(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Алексион Фармасьютикалз, Инк. filed Critical Алексион Фармасьютикалз, Инк.
Publication of RU2008139118A publication Critical patent/RU2008139118A/ru
Application granted granted Critical
Publication of RU2445975C2 publication Critical patent/RU2445975C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
RU2008139118/15A 2006-03-02 2007-03-02 Продление срока выживаемости аллотрансплантата путем ингибирования активности комплемента RU2445975C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77885906P 2006-03-02 2006-03-02
US60/778,859 2006-03-02

Publications (2)

Publication Number Publication Date
RU2008139118A RU2008139118A (ru) 2010-04-10
RU2445975C2 true RU2445975C2 (ru) 2012-03-27

Family

ID=38475394

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2008139118/15A RU2445975C2 (ru) 2006-03-02 2007-03-02 Продление срока выживаемости аллотрансплантата путем ингибирования активности комплемента

Country Status (21)

Country Link
US (1) US20100135992A1 (enExample)
EP (2) EP2918269A1 (enExample)
JP (2) JP5722524B2 (enExample)
KR (2) KR101527225B1 (enExample)
CN (1) CN101437501B (enExample)
AU (1) AU2007224250B2 (enExample)
BR (1) BRPI0708424A2 (enExample)
CA (1) CA2644020C (enExample)
DK (1) DK1988882T3 (enExample)
ES (1) ES2530637T3 (enExample)
HR (1) HRP20150182T1 (enExample)
IL (1) IL193623A0 (enExample)
MX (1) MX2008011054A (enExample)
NZ (1) NZ570802A (enExample)
PL (1) PL1988882T3 (enExample)
PT (1) PT1988882E (enExample)
RS (1) RS53864B1 (enExample)
RU (1) RU2445975C2 (enExample)
SG (1) SG171578A1 (enExample)
SI (1) SI1988882T1 (enExample)
WO (1) WO2007103134A2 (enExample)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2742606C2 (ru) * 2015-12-18 2021-02-09 Чугаи Сейяку Кабусики Кайся Антитела к с5 и способы их применения
US11046784B2 (en) 2006-03-31 2021-06-29 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
US11248053B2 (en) 2007-09-26 2022-02-15 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
US11359194B2 (en) 2008-04-11 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding two or more antigen molecules repeatedly
US11597760B2 (en) 2014-12-19 2023-03-07 Chugai Seiyaku Kabushiki Kaisha Method of detecting the presence of complement C5
US11780912B2 (en) 2016-08-05 2023-10-10 Chugai Seiyaku Kabushiki Kaisha Composition for prophylaxis or treatment of IL-8 related diseases
US11891434B2 (en) 2010-11-30 2024-02-06 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
US12169205B2 (en) 2014-12-19 2024-12-17 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
US12595299B2 (en) 2015-02-05 2026-04-07 Chugai Seiyaku Kabushiki Kaisha FC variants

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE066795T2 (hu) 2006-03-15 2024-09-28 Alexion Pharma Inc Paroxysmalis nocturnalis haemoglobinuriában szenvedõ betegek kezelése egy komplement inhibitorral
WO2008030505A2 (en) * 2006-09-05 2008-03-13 Alexion Pharmaceuticals, Inc. Methods and compositions for the treatment of antibody mediated neuropathies
LT3028716T (lt) 2006-10-10 2020-12-10 Regenesance B.V. Komplemento slopinimas nervų regeneracijos pagerinimui
JP6223659B2 (ja) * 2008-11-10 2017-11-01 アレクシオン ファーマシューティカルズ， インコーポレイテッド 補体関連障害を処置するための方法および組成物
US20130028897A1 (en) * 2009-04-27 2013-01-31 Ali Naji Methods for reducing the level of alloantibodies in a subject
NZ597259A (en) * 2009-06-23 2014-04-30 Alexion Pharma Inc Bispecific antibodies that bind to complement proteins
JP5871798B2 (ja) * 2009-07-02 2016-03-01 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント 肝再生を刺激する方法
CN101621801B (zh) * 2009-08-11 2012-11-28 华为终端有限公司 无线局域网的认证方法、系统及服务器、终端
AU2012256281B2 (en) * 2011-05-16 2017-06-15 Genzyme Corporation Induction of immune tolerance by using methotrexate
CN102585016B (zh) * 2012-03-06 2014-06-04 江苏健德生物药业有限公司 一种可同时抑制t、b淋巴细胞功能的免疫融合蛋白、其制备方法及其应用
CN103232542B (zh) * 2013-02-01 2015-05-13 殷勇 一种双靶标嵌合蛋白
AU2014306002B2 (en) 2013-08-07 2017-05-25 Alexion Pharmaceuticals, Inc. Atypical hemolytic uremic syndrome (aHUS) biomarker proteins
EP3033093A1 (en) * 2013-08-16 2016-06-22 Alexion Pharmaceuticals, Inc. Treatment of graft rejection by administering a complement inhibitor to an organ prior to transplant
ME03318B (me) * 2013-11-22 2019-10-20 Shire Viropharma Inc Postupci lečenja odbacivanja posredovanog antitelima pacijenata sa transplatiranim organom sa inhibitorom c1-esteraze
NZ711451A (en) * 2014-03-07 2016-05-27 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
EP3294342A4 (en) 2015-05-08 2018-11-07 President and Fellows of Harvard College Universal donor stem cells and related methods
EP3368073B1 (en) * 2015-10-30 2024-05-15 Alexion Pharmaceuticals, Inc. A method of inhibiting exacerbations of t cell-mediated allograft vasculopathy
CA3024618A1 (en) 2016-05-27 2017-11-30 Alexion Pharmaceuticals, Inc. Methods for treatment of refractory generalized myasthenia gravis
WO2017212391A1 (en) * 2016-06-07 2017-12-14 Novartis Ag An anti-c5 antibody dosing regimen
EP3463459A1 (en) * 2016-06-07 2019-04-10 Novartis AG Tesidolumab for use in the treatment of transplant rejection
IL263481B2 (en) 2016-06-14 2024-06-01 Regeneron Pharma Anti-c5 antibodies and uses thereof
ES2965486T3 (es) 2017-07-27 2024-04-15 Alexion Pharma Inc Formulaciones de anticuerpos anti-C5 de alta concentración
JP7518764B2 (ja) 2017-10-26 2024-07-18 アレクシオン ファーマシューティカルズ， インコーポレイテッド 発作性夜間ヘモグロビン尿症（ＰＮＨ）および非典型溶血性尿毒症症候群（ａＨＵＳ）の処置のための抗Ｃ５抗体の投薬量および投与
AU2018383751B2 (en) 2017-12-13 2025-05-08 Regeneron Pharmaceuticals, Inc. Anti-C5 antibody combinations and uses thereof
US20190247560A1 (en) 2018-02-13 2019-08-15 Gambro Lundia Ab Extracorporeal devices and methods of treating complement factor related diseases
EP3802593B1 (en) 2018-05-31 2024-09-11 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) in pediatric patients
EP3802603A1 (en) 2018-06-04 2021-04-14 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of atypical hemolytic uremic syndrome (ahus) in pediatric patients
JP7538723B2 (ja) 2018-06-28 2024-08-22 アレクシオン ファーマシューティカルズ， インコーポレイテッド 抗ｃ５抗体の産生方法
US12240893B2 (en) 2018-10-30 2025-03-04 Alexion Pharmaceuticals, Inc. Subcutaneous dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH)
CN111449050A (zh) * 2019-01-20 2020-07-28 睿诺医疗科技（上海）有限公司 环孢菌素类似物及其用途
US20220213434A1 (en) 2019-05-10 2022-07-07 The Regents Of The University Of California Modified pluripotent cells
US11162079B2 (en) 2019-05-10 2021-11-02 The Regents Of The University Of California Blood type O Rh-hypo-immunogenic pluripotent cells
CN116870135A (zh) 2019-10-12 2023-10-13 睿诺医疗科技（上海）有限公司 肾毒素诱发的肾损伤的治疗和预防
EP4585223A3 (en) * 2020-01-15 2025-07-30 The Regents of the University of California Transplanted cell protection via inhibition of polymorphonuclear cells
AU2021256222A1 (en) 2020-04-15 2022-10-06 Farsight Medical Technology (Shanghai) Co., Ltd. Prevention and treatment of organ injuries
CN116194478A (zh) 2020-06-24 2023-05-30 阿雷克森制药公司 皮下（sc）施用抗c5抗体治疗补体相关病症
CA3215371A1 (en) * 2021-04-13 2022-10-20 Shibeshih Mitiku BELACHEW Compositions and methods for treating chronic active white matter lesions / radiologically isolated syndrome
CN114532982A (zh) * 2022-01-12 2022-05-27 高谋 评价干细胞系统移植调控补体活化作用的体系

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2169009C2 (ru) * 1994-04-25 2001-06-20 Трастиз Оф Дартмут Колледж Способы индуцирования т-клеточной толерантности к тканевому или органному трансплантату
RU2174405C2 (ru) * 1997-10-23 2001-10-10 Сэнгстат Медикал Корпорейшн Композиция циклоспорина для перорального введения (варианты) и способ достижения иммуносупрессии в организме реципиента

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2588579B2 (ja) 1988-04-21 1997-03-05 株式会社クラレ 耐熱水性にすぐれたポリビニルアルコール系繊維およびその製造法
US5705732A (en) * 1989-06-12 1998-01-06 Oklahoma Medical Research Foundation Universal donor cells
US5135916A (en) * 1989-06-12 1992-08-04 Oklahoma Medical Research Foundation Inhibition of complement mediated inflammatory response
US5573940A (en) 1989-06-12 1996-11-12 Oklahoma Medical Research Foundation Cells expressing high levels of CD59
US20010018051A1 (en) * 1990-04-09 2001-08-30 White David James Graham Inhibition of allograft and concordant xenograft rejection
CA2097825A1 (en) 1990-12-06 1992-06-07 Henry C. Marsh, Jr. Synergistic compositions of soluble complement receptors and compounds that inhibit complement and/or suppress immune activity
US5456909A (en) * 1992-08-07 1995-10-10 T Cell Sciences, Inc. Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo
US5308341A (en) 1993-09-28 1994-05-03 Becton, Dickinson And Company Method of testing the dose accuracy of a medication delivery device
US6074642A (en) * 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5679345A (en) * 1994-06-02 1997-10-21 The Johns Hopkins University Method for preventing complement-dependent rejection of organ or tissue transplants
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6355242B1 (en) * 1997-05-23 2002-03-12 Ixion Biotechnology, Inc. Materials and methods for treating or preventing oxalate-related disease
IL137614A0 (en) * 1998-02-04 2001-07-24 Gen Hospital Corp An inhibitor of a costimulatory pathway and hematopoietic stem cells for promoting graft acceptance
US6302855B1 (en) 1998-05-20 2001-10-16 Novo Nordisk A/S Medical apparatus for use by a patient for medical self treatment of diabetes
AU1521000A (en) 1998-11-06 2000-05-29 Schepens Eye Research Institute, Inc., The Local use of soluble tumor necrosis receptor i (stnfri) for prophylaxis and treatment of corneal transplant rejection and other disorders of the eye
US6192891B1 (en) 1999-04-26 2001-02-27 Becton Dickinson And Company Integrated system including medication delivery pen, blood monitoring device, and lancer
AUPQ431299A0 (en) 1999-11-26 1999-12-23 Unisearch Limited Method of inducing immune tolerance
US6538028B1 (en) * 2000-02-01 2003-03-25 Vanderbilt University Method for inhibiting complement activation
ATE449791T1 (de) 2000-10-10 2009-12-15 Genentech Inc Inhibierung von c5 komplement-aktivierung für die behandlung und vorbeugung von xeno-transplantat oder akute vaskuläre abstossung
ES2322442T3 (es) * 2001-06-08 2009-06-22 Novartis Ag Tratamiento o profilaxis del rechazo de injertos de celulas productoras de insulina.
MXPA04001301A (es) 2001-08-17 2004-07-08 Tanox Inc Inhibidores de la ruta del complemento que se unen a c5 y c5a son evitar la formacion de c5b.
US20030180301A1 (en) * 2002-01-22 2003-09-25 Shaf Keshavjee Use of TGF-beta antagonists to treat or to prevent chronic transplant rejection
US20040146503A1 (en) * 2002-08-28 2004-07-29 Tesi Raymond J. Methods and compositions for inducing stable immune tolerance
WO2005025509A2 (en) * 2003-09-11 2005-03-24 Board Of Regents, The University Of Texas System Methods and materials for treating autoimmune diseases and conditions
US20050169921A1 (en) * 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
EP2338511A3 (en) * 2004-05-14 2012-07-25 Alexion Pharmaceuticals, Inc. Prolongation of survival of an allograft by inhibiting complement activity
MXPA06013463A (es) * 2004-05-17 2007-03-01 Combinatorx Inc Metodos y reactivos para el tratamiento de desordenes inmuno-inflamatorios.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2169009C2 (ru) * 1994-04-25 2001-06-20 Трастиз Оф Дартмут Колледж Способы индуцирования т-клеточной толерантности к тканевому или органному трансплантату
RU2174405C2 (ru) * 1997-10-23 2001-10-10 Сэнгстат Медикал Корпорейшн Композиция циклоспорина для перорального введения (варианты) и способ достижения иммуносупрессии в организме реципиента

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MIN WP et al. Synergistic tolerance induced by LF 15-0195 and anti-CD45RB monoclonal antibody through suppressive dendritic cells// Transplantation. 2003 Apr 27; 75(8):1160-5. реферат, онлайн [Найдено в Интернет на www.pubmed.com 24.12.2010], РМID: 12717196 [PubMed - indexed for MEDLINE]. ZHOU D et al. LF 15-0195, a novel immunosuppressive agent prevents rejection and induces operational tolerance in a mouse cardiac allograft model // Transplantation. 2003 Aug 27; 76(4):644-50 реферат, онлайн [Найдено в Интернет на www.pubmed.com 24.12.2010], PMID: 12973102 [PubMed - indexed for MEDLINE]. *

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11046784B2 (en) 2006-03-31 2021-06-29 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
US12473375B2 (en) 2006-03-31 2025-11-18 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
US12116414B2 (en) 2007-09-26 2024-10-15 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
US11248053B2 (en) 2007-09-26 2022-02-15 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
US12122840B2 (en) 2007-09-26 2024-10-22 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
US11359194B2 (en) 2008-04-11 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding two or more antigen molecules repeatedly
US11371039B2 (en) 2008-04-11 2022-06-28 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
US11891434B2 (en) 2010-11-30 2024-02-06 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
US12617847B2 (en) 2010-11-30 2026-05-05 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
US11597760B2 (en) 2014-12-19 2023-03-07 Chugai Seiyaku Kabushiki Kaisha Method of detecting the presence of complement C5
US12169205B2 (en) 2014-12-19 2024-12-17 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
US12595299B2 (en) 2015-02-05 2026-04-07 Chugai Seiyaku Kabushiki Kaisha FC variants
RU2742606C2 (ru) * 2015-12-18 2021-02-09 Чугаи Сейяку Кабусики Кайся Антитела к с5 и способы их применения
US11780912B2 (en) 2016-08-05 2023-10-10 Chugai Seiyaku Kabushiki Kaisha Composition for prophylaxis or treatment of IL-8 related diseases
US12516115B2 (en) 2016-08-05 2026-01-06 Chugai Seiyaku Kabushiki Kaisha Composition for prophylaxis or treatment of IL-8 related diseases

Also Published As

Publication number Publication date
NZ570802A (en) 2012-03-30
AU2007224250B2 (en) 2012-05-03
US20100135992A1 (en) 2010-06-03
PL1988882T3 (pl) 2015-04-30
JP5722524B2 (ja) 2015-05-20
KR101527225B1 (ko) 2015-06-08
HRP20150182T1 (hr) 2015-06-05
KR101650264B1 (ko) 2016-08-22
MX2008011054A (es) 2009-03-03
PT1988882E (pt) 2015-02-17
SI1988882T1 (sl) 2015-07-31
CN101437501A (zh) 2009-05-20
ES2530637T3 (es) 2015-03-04
JP2013155202A (ja) 2013-08-15
WO2007103134A2 (en) 2007-09-13
CN101437501B (zh) 2012-09-05
BRPI0708424A2 (pt) 2011-05-31
EP1988882B1 (en) 2014-12-17
EP1988882A2 (en) 2008-11-12
WO2007103134A3 (en) 2008-09-12
KR20080098543A (ko) 2008-11-10
KR20140124023A (ko) 2014-10-23
HK1120444A1 (en) 2009-04-03
AU2007224250A1 (en) 2007-09-13
JP2009528369A (ja) 2009-08-06
SG171578A1 (en) 2011-06-29
CA2644020A1 (en) 2007-09-13
IL193623A0 (en) 2009-08-03
CA2644020C (en) 2016-05-10
RS53864B1 (sr) 2015-08-31
EP2918269A1 (en) 2015-09-16
DK1988882T3 (en) 2015-02-23
RU2008139118A (ru) 2010-04-10

Similar Documents

Publication Publication Date Title
DK1988882T3 (en) PROLONGED SURVIVAL OF A allograft by inhibiting complement activity
US20190309053A1 (en) Prolongation of survival of an allograft by inhibiting complement activity
HK1120444B (en) Prolongation of survival of an allograft by inhibiting complement activity
AU2011236106A1 (en) Prolongation of survival of an allograft by inhibiting complement activity
HK1157199A (en) Prolongation of survival of an allograft by inhibiting complement activity
HK1101962B (en) Prolongation of survival of an allograft by inhibiting complement activity

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20190303